Logo image of TVRD

TVARDI THERAPEUTICS INC (TVRD) Stock Fundamental Analysis

USA - NASDAQ:TVRD - US1407553072 - Common Stock

4.19 USD
0 (0%)
Last: 11/11/2025, 8:00:01 PM
4.28 USD
+0.09 (+2.15%)
After Hours: 11/11/2025, 8:00:01 PM
Fundamental Rating

2

Taking everything into account, TVRD scores 2 out of 10 in our fundamental rating. TVRD was compared to 191 industry peers in the Pharmaceuticals industry. While TVRD seems to be doing ok healthwise, there are quite some concerns on its profitability. TVRD has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

TVRD had negative earnings in the past year.
In the past year TVRD has reported a negative cash flow from operations.
In the past 5 years TVRD reported 4 times negative net income.
TVRD had a negative operating cash flow in each of the past 5 years.
TVRD Yearly Net Income VS EBIT VS OCF VS FCFTVRD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M -100M

1.2 Ratios

TVRD's Return On Assets of -115.70% is on the low side compared to the rest of the industry. TVRD is outperformed by 80.10% of its industry peers.
Industry RankSector Rank
ROA -115.7%
ROE N/A
ROIC N/A
ROA(3y)-100.93%
ROA(5y)-67.1%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TVRD Yearly ROA, ROE, ROICTVRD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

TVRD's Gross Margin of 86.08% is amongst the best of the industry. TVRD outperforms 89.01% of its industry peers.
TVRD does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 86.08%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TVRD Yearly Profit, Operating, Gross MarginsTVRD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K -50K

More info and screens

4

2. Health

2.1 Basic Checks

TVRD does not have a ROIC to compare to the WACC, probably because it is not profitable.
TVRD has more shares outstanding than it did 1 year ago.
The number of shares outstanding for TVRD has been increased compared to 5 years ago.
TVRD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TVRD Yearly Shares OutstandingTVRD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
TVRD Yearly Total Debt VS Total AssetsTVRD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -27.86, we must say that TVRD is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -27.86, TVRD is not doing good in the industry: 86.91% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -27.86
ROIC/WACCN/A
WACC8.92%
TVRD Yearly LT Debt VS Equity VS FCFTVRD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

TVRD has a Current Ratio of 32.48. This indicates that TVRD is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of TVRD (32.48) is better than 97.91% of its industry peers.
A Quick Ratio of 31.73 indicates that TVRD has no problem at all paying its short term obligations.
TVRD has a Quick ratio of 31.73. This is amongst the best in the industry. TVRD outperforms 97.91% of its industry peers.
Industry RankSector Rank
Current Ratio 32.48
Quick Ratio 31.73
TVRD Yearly Current Assets VS Current LiabilitesTVRD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

2

3. Growth

3.1 Past

TVRD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -37.11%.
TVRD shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -49.96%.
TVRD shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.21% yearly.
EPS 1Y (TTM)-37.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.49%
Revenue 1Y (TTM)-49.96%
Revenue growth 3Y-46.26%
Revenue growth 5Y9.21%
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, TVRD will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.25% on average per year.
The Revenue is expected to decrease by -14.87% on average over the next years. This is quite bad
EPS Next Y98.33%
EPS Next 2Y39.88%
EPS Next 3Y25.29%
EPS Next 5Y14.25%
Revenue Next Year-82.49%
Revenue Next 2Y-89.11%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
TVRD Yearly Revenue VS EstimatesTVRD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2029 2030 2031 2032 50M 100M 150M
TVRD Yearly EPS VS EstimatesTVRD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -20 -40 -60 -80

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TVRD. In the last year negative earnings were reported.
Also next year TVRD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TVRD Price Earnings VS Forward Price EarningsTVRD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TVRD Per share dataTVRD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60

4.3 Compensation for Growth

TVRD's earnings are expected to grow with 25.29% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.88%
EPS Next 3Y25.29%

More info and screens

0

5. Dividend

5.1 Amount

TVRD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TVARDI THERAPEUTICS INC

NASDAQ:TVRD (11/11/2025, 8:00:01 PM)

After market: 4.28 +0.09 (+2.15%)

4.19

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-12 2025-11-12/amc
Inst Owners20.85%
Inst Owner Change1.64%
Ins Owners19.12%
Ins Owner Change0%
Market Cap39.30M
Revenue(TTM)20.97M
Net Income(TTM)-45.06M
Analysts77.14
Price Target20.11 (379.95%)
Short Float %22.06%
Short Ratio4.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)49.63%
Min Revenue beat(2)-10.63%
Max Revenue beat(2)109.89%
Revenue beat(4)2
Avg Revenue beat(4)34.26%
Min Revenue beat(4)-17.21%
Max Revenue beat(4)109.89%
Revenue beat(8)4
Avg Revenue beat(8)5.44%
Revenue beat(12)7
Avg Revenue beat(12)0.17%
Revenue beat(16)9
Avg Revenue beat(16)-1.11%
PT rev (1m)-65.5%
PT rev (3m)-63.47%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-20.51%
EPS NY rev (3m)-40.53%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-37.5%
Revenue NY rev (3m)-50%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.19
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-78.48
EYN/A
EPS(NY)-3.39
Fwd EYN/A
FCF(TTM)-3.82
FCFYN/A
OCF(TTM)-3.8
OCFYN/A
SpS0.81
BVpS-0.86
TBVpS-0.86
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -115.7%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 86.08%
FCFM N/A
ROA(3y)-100.93%
ROA(5y)-67.1%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 32.48
Quick Ratio 31.73
Altman-Z -27.86
F-Score6
WACC8.92%
ROIC/WACCN/A
Cap/Depr(3y)492.59%
Cap/Depr(5y)332.09%
Cap/Sales(3y)8.69%
Cap/Sales(5y)5.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-37.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.49%
EPS Next Y98.33%
EPS Next 2Y39.88%
EPS Next 3Y25.29%
EPS Next 5Y14.25%
Revenue 1Y (TTM)-49.96%
Revenue growth 3Y-46.26%
Revenue growth 5Y9.21%
Sales Q2Q%-100%
Revenue Next Year-82.49%
Revenue Next 2Y-89.11%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y76.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.9%
EBIT Next 3Y10.58%
EBIT Next 5YN/A
FCF growth 1Y59.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y59.45%
OCF growth 3YN/A
OCF growth 5YN/A

TVARDI THERAPEUTICS INC / TVRD FAQ

What is the fundamental rating for TVRD stock?

ChartMill assigns a fundamental rating of 2 / 10 to TVRD.


Can you provide the valuation status for TVARDI THERAPEUTICS INC?

ChartMill assigns a valuation rating of 1 / 10 to TVARDI THERAPEUTICS INC (TVRD). This can be considered as Overvalued.


How profitable is TVARDI THERAPEUTICS INC (TVRD) stock?

TVARDI THERAPEUTICS INC (TVRD) has a profitability rating of 1 / 10.


What is the earnings growth outlook for TVARDI THERAPEUTICS INC?

The Earnings per Share (EPS) of TVARDI THERAPEUTICS INC (TVRD) is expected to grow by 98.33% in the next year.